# Keba Biological (Jiangsu) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keba-biological-jiangsu-co

- Industry: Biotechnology
- Headquarters: Grand Cayman, Cayman Islands
- Total disclosed funding: $30M
- Latest round: Series B (Dec 31, 2021)
- Investors on record: 4

## About

Based in Grand Cayman, Cayman Islands, and founded in 2021, Keba Biological (Jiangsu) Co., Ltd., dba SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates. Dr. Gui-Dong Zhu is the president and CEO of the company. In December 2021, Keba Biological (Jiangsu) Co., Ltd. raised USD 30 million in Series B funding co-led by HighLight Capital and Rotating Boulder Fund including Sangel Capital and Bosi Gongchuang.

The company develops anticancer biologics utilizing the company's integrated platform for bispecific antibodies and antibody-drug conjugates. The firm provides an integrated multi-component SAILING™ antibody discovery platform combined with a sophisticated AI-based target mining algorithm, which yields multiple IND-ready drug candidates. The organization focuses on process development and commercial production.

The enterprise plans to the December 2021 funding primarily for moving the current four biological drug candidates into various stages of clinical development.

## Funding rounds

- Series B, Dec 31, 2021, $30M — HighLight Capital, Sangel Capital, Rotating Boulder Fund, Bosi Gongchuang

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series B
- Rotating Boulder Fund (https://capitalatlas.ai/funds/rotating-boulder-fund) — Series B
- Bosi Gongchuang — Series B